^
    BIOMARKER:

    KRAS wild-type

    i
    Other names: KRAS, KRAS proto-oncogene GTPase, KRAS1, KRAS2, NS, NS3, OES, CFC2, RALD, K-Ras, RASK2, KI-RAS, C-K-RAS, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras 2, C-K-RAS, c-Ki-ras, c-Ki-ras2, Kirsten rat sarcoma viral oncogene homolog
    Entrez ID:
    3845
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    KRAS wild-type
    Ovarian Cancer
    VS-6766 + VS-6063
    Sensitive: B - Late Trials
    KRAS wild-type
    Pancreatic Ductal Adenocarcinoma
    gemcitabine + albumin-bound paclitaxel
    Sensitive: B - Late Trials
    KRAS wild-type
    Pancreatic Ductal Adenocarcinoma
    5-fluorouracil + oxaliplatin
    Sensitive: B - Late Trials
    KRAS wild-type
    CRC
    cetuximab + palbociclib
    Sensitive: C2 – Inclusion Criteria
    KRAS wild-type
    CRC
    cetuximab
    Sensitive: C2 – Inclusion Criteria
    KRAS wild-type
    CRC
    bevacizumab
    Sensitive: C2 – Inclusion Criteria
    KRAS wild-type
    Biliary Tract Cancer
    panitumumab
    Sensitive: C2 – Inclusion Criteria
    KRAS wild-type
    CRC
    cetuximab
    Resistant: C3 – Early Trials
    KRAS wild-type
    CRC
    panitumumab + cabozantinib tablet
    Sensitive: C3 – Early Trials
    KRAS wild-type
    CRC
    SIRB
    Sensitive: C3 – Early Trials
    KRAS wild-type
    CRC
    MM-121
    Sensitive: D – Preclinical